“2025 promises to be another milestone year for our rapidly advancing pipeline with important Phase III data readouts for programs including across our general medicine, rare disease, inflammation and oncology portfolios.”

In context

“indications for UPLIZNA, further strengthening the growth trajectory of our rare disease business. In inflammation, we continue to be inspired by the strong performance of TEZSPIRE and the progress we're making advancing into new indications, including COPD, which is the third leading cause of death, where we intend to initiate Phase III studies; and of course, in chronic rhinosinusitis, which runs in parallel with other respiratory diseases. In oncology, our leading bispecific T-cell engager platform provides further opportunities for growth with BLINCYTO moving into frontline treatment and demonstrating compelling survival benefit in B-ALL. IMDELLTRA showing impressive efficacy in hard-to-treat small cell lung cancer and xaluritamig advancing into Phase III in advanced prostate cancer. 2025 promises to be another milestone year for our rapidly advancing pipeline with important Phase III data readouts for programs including across our general medicine, rare disease, inflammation and oncology portfolios. Beyond these readouts, we'll be initiating several new Phase III trials of MariTide in obesity and related conditions. This is an exciting time for innovation in our laboratories, in our factories with the science and manufacturing and in leveraging technology across the company. When it comes to artificial intelligence, we're finding new opportunities across our business, and AI is helping us deliver innovative medicines to more patients even faster. To wrap up, 2024 demonstrated the strength of our business, the depth and breadth of our portfolio and the power of our pipeline. As we step into 2025, we're poised to deliver continued growth and innovation in the near term, through 2030 and beyond. And I want to thank our global team for their exceptional contributions and dedication to ou”